World Investment Advisors Has $11.79 Million Stock Position in IQVIA Holdings Inc. (NYSE:IQV)

World Investment Advisors lowered its stake in IQVIA Holdings Inc. (NYSE:IQV - Free Report) by 2.9% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 59,989 shares of the medical research company's stock after selling 1,760 shares during the period. World Investment Advisors' holdings in IQVIA were worth $11,788,000 as of its most recent SEC filing.

Other institutional investors have also added to or reduced their stakes in the company. Synergy Asset Management LLC bought a new position in shares of IQVIA during the fourth quarter valued at approximately $33,000. Lee Danner & Bass Inc. bought a new position in shares of IQVIA during the 4th quarter valued at $44,000. Zions Bancorporation N.A. grew its stake in shares of IQVIA by 55.2% during the 4th quarter. Zions Bancorporation N.A. now owns 239 shares of the medical research company's stock valued at $47,000 after purchasing an additional 85 shares during the period. Versant Capital Management Inc increased its holdings in IQVIA by 46.0% during the fourth quarter. Versant Capital Management Inc now owns 295 shares of the medical research company's stock valued at $58,000 after buying an additional 93 shares during the last quarter. Finally, SBI Securities Co. Ltd. purchased a new position in IQVIA during the fourth quarter valued at $60,000. Hedge funds and other institutional investors own 89.62% of the company's stock.

Analyst Ratings Changes

Several research analysts have weighed in on the company. Bank of America dropped their price target on IQVIA from $255.00 to $235.00 and set a "buy" rating for the company in a research note on Friday, December 13th. Truist Financial reiterated a "buy" rating and set a $263.00 price objective (up previously from $261.00) on shares of IQVIA in a research report on Monday, February 10th. StockNews.com cut IQVIA from a "buy" rating to a "hold" rating in a research note on Wednesday, March 12th. Barclays lowered their target price on shares of IQVIA from $255.00 to $235.00 and set an "overweight" rating for the company in a research note on Monday, February 3rd. Finally, Royal Bank of Canada reaffirmed an "outperform" rating and issued a $270.00 price target on shares of IQVIA in a report on Monday, February 10th. Five research analysts have rated the stock with a hold rating, sixteen have assigned a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, IQVIA presently has an average rating of "Moderate Buy" and a consensus price target of $249.05.

IQVIA Stock Performance

Shares of NYSE:IQV traded down $0.59 during trading on Tuesday, hitting $152.42. 647,671 shares of the company traded hands, compared to its average volume of 1,329,102. IQVIA Holdings Inc. has a one year low of $146.06 and a one year high of $252.88. The company has a quick ratio of 0.84, a current ratio of 0.84 and a debt-to-equity ratio of 2.12. The stock has a market capitalization of $26.87 billion, a price-to-earnings ratio of 20.41, a PEG ratio of 1.99 and a beta of 1.46. The business's fifty day moving average is $188.58 and its 200-day moving average is $202.90.

IQVIA (NYSE:IQV - Get Free Report) last posted its quarterly earnings data on Thursday, February 6th. The medical research company reported $2.90 EPS for the quarter, missing analysts' consensus estimates of $3.11 by ($0.21). IQVIA had a return on equity of 28.81% and a net margin of 8.91%. As a group, equities analysts predict that IQVIA Holdings Inc. will post 10.84 earnings per share for the current fiscal year.

About IQVIA

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.